Related Experiment Video

Updated: Apr 26, 2026

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

13.1K

[Characterization of patients with chronic hepatitis B virus infection without indication for treatment]

Ramon Planas1

  • 1Unidad de Hepatología, CIBERehd, Servicio de Aparato Digestivo, Hospital Germans Trias i Pujol, Badalona, Barcelona, España.

Gastroenterologia Y Hepatologia
|August 5, 2014
PubMed

Insights

Hepatitis B virus (HBV) infection management has gray areas. Treatment may be considered for healthcare workers and pregnant women, and for inactive carriers with cirrhosis or high viral loads.

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Context:

  • Chronic Hepatitis B Virus (HBV) infection involves complex interactions between viral replication and host immunity.
  • Current European guidelines suggest no treatment for immune-tolerant and inactive carrier phases of chronic HBV.
  • Certain 'gray areas' within these phases present challenges in patient categorization and treatment decisions.

Purpose:

  • To identify specific scenarios within the immune-tolerant and inactive carrier phases where HBV treatment initiation may be warranted.
  • To refine clinical decision-making for chronic HBV management beyond standard guidelines.

Summary:

  • Treatment for immune-tolerant HBV may be indicated for healthcare professionals performing invasive procedures.
  • Antiviral therapy during the third trimester of pregnancy is recommended for HBeAg-positive, normal ALT, high HBV DNA pregnant women to prevent vertical transmission.
  • For inactive carriers (HBeAg-negative, normal ALT, HBV DNA ≥ 2000 IU/mL), treatment indication depends on hepatic lesion severity; cirrhosis necessitates treatment if HBV DNA is detectable.

Impact:

  • Provides nuanced guidance for managing chronic HBV in specific patient populations.
  • Aims to optimize treatment strategies, reduce vertical transmission, and prevent disease progression.
  • Supports clinical decision-making in complex chronic HBV infection cases.

Keywords:
Chronic hepatitis BHBsAg valuesHepatitis crónica BImmune tolerantInactive HBV carrierPortador inactivo del VHBTolerancia inmuneValores del HBsAg

More Related Videos

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

5.5K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
78
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
18
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
24
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
379
Chronic Pancreatitis I: Introduction01:25

Chronic Pancreatitis I: Introduction

Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80%...
24